TCT 736: Cost Effectiveness Analysis of the OPTION Trial: Left Atrial Appendage Closure after Ablation for Non-Valvular Atrial Fibrillation

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker’s Bureau - Boston Scientific Corporation; Medtronic; Abbott; Biosense Webster; Siemens Healthineers</li><li>Grant Support/Research Contract - Boston Scientific Corporation; Medtronic; Abbott; Biosense Webster; Siemens Healthineers</li></ul>